Loading stock data…
CytoMed Therapeutics Limited (GDTC)
$1.00-0.02 (-1.96%)
After Hours$0.94-0.06 (-6.00%)· Last close Jun 29
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytoMed Therapeutics Limited in the Healthcare sector is trading at $1.00 with a market capitalization of $14M. The stock is currently near its 52-week low of $0.68, remaining 28.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
4,743
Recent News
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects
As February begins, major U.S. stock indexes have shown a robust start, with the Dow Jones Industrial Average and S&P 500 posting significant gains. In such an optimistic market climate, investors often look beyond the well-known giants to explore opportunities in lesser-known areas like penny stocks. Though traditionally associated with high risk, penny stocks can offer intriguing prospects when supported by solid financials. This article will highlight three such companies that may provide...
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s resea